JBIO vs. CRSP

Last updated Apr 2, 2026

Compare and contrast key facts about Jade Biosciences, Inc (JBIO) and CRISPR Therapeutics AG (CRSP).

Performance

JBIO vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Jade Biosciences, Inc (JBIO) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

JBIO vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
JBIO Jade Biosciences, Inc	3.82%	59.23%	-88.29%	-22.76%	148.52%	-48.36%
CRSP CRISPR Therapeutics AG	-6.92%	33.23%	-37.12%	54.00%	-46.36%	-53.19%

Fundamentals

EPS JBIO : -$3.26 CRSP : -$5.47
Total Revenue (TTM) JBIO : $0.00 CRSP : $36.75M
Gross Profit (TTM) JBIO : -$17.00K CRSP : -$130.60M
EBITDA (TTM) JBIO : -$94.71M CRSP : -$529.50M

Returns By Period

In the year-to-date period, JBIO achieves a 3.82% return, which is significantly higher than CRSP's -6.92% return.

JBIO

• 1D: 14.02%
• 1M: 13.46%
• YTD: 3.82%
• 6M: 75.85%
• 1Y: 74.54%
• 3Y*: -39.89%
• 5Y*: —
• 10Y*: —

CRSP

• 1D: 2.61%
• 1M: -19.68%
• YTD: -6.92%
• 6M: -26.22%
• 1Y: 47.28%
• 3Y*: 2.57%
• 5Y*: -16.38%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

JBIO vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JBIO

JBIO Risk / Return Rank: 70
JBIO Sharpe Ratio Rank: 71
JBIO Sortino Ratio Rank: 72
JBIO Omega Ratio Rank: 68
JBIO Calmar Ratio Rank: 71
JBIO Martin Ratio Rank: 65

CRSP

CRSP Risk / Return Rank: 64
CRSP Sharpe Ratio Rank: 66
CRSP Sortino Ratio Rank: 67
CRSP Omega Ratio Rank: 62
CRSP Calmar Ratio Rank: 63
CRSP Martin Ratio Rank: 60

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JBIO vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Jade Biosciences, Inc (JBIO) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	JBIO	CRSP	Difference
Sharpe ratio Return per unit of total volatility	0.94	0.75	+0.19
Sortino ratio Return per unit of downside risk	1.77	1.50	+0.28
Omega ratio Gain probability vs. loss probability	1.21	1.17	+0.04
Calmar ratio Return relative to maximum drawdown	1.63	1.03	+0.60
Martin ratio Return relative to average drawdown	2.90	2.03	+0.86
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

JBIO vs. CRSP - Sharpe Ratio Comparison

The current JBIO Sharpe Ratio is 0.94, which is comparable to the CRSP Sharpe Ratio of 0.75. The chart below compares the historical Sharpe Ratios of JBIO and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	JBIO	CRSP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.94	0.75	+0.19
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.27	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.31	0.22	-0.53

Correlation

The correlation between JBIO and CRSP is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

JBIO vs. CRSP - Dividend Comparison

JBIO's dividend yield for the trailing twelve months is around 14.98%, while CRSP has not paid dividends to shareholders.

	TTM	2025
JBIO Jade Biosciences, Inc	14.98%	15.55%
CRSP CRISPR Therapeutics AG	0.00%	0.00%

Drawdowns

JBIO vs. CRSP - Drawdown Comparison

The maximum JBIO drawdown since its inception was -95.41%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for JBIO and CRSP.

Drawdown Indicators

	JBIO	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-95.41%	-85.11%	-10.30%
Max Drawdown (1Y) Largest decline over 1 year	-45.83%	-42.25%	-3.58%
Max Drawdown (5Y) Largest decline over 5 years	—	-80.68%	—
Current Drawdown Current decline from peak	-85.75%	-76.76%	-8.99%
Average Drawdown Average peak-to-trough decline	-56.56%	-48.71%	-7.85%
Ulcer Index Depth and duration of drawdowns from previous peaks	25.73%	21.35%	+4.38%

Volatility

JBIO vs. CRSP - Volatility Comparison

Jade Biosciences, Inc (JBIO) and CRISPR Therapeutics AG (CRSP) have volatilities of 17.72% and 18.14%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JBIO	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.72%	18.14%	-0.42%
Volatility (6M) Calculated over the trailing 6-month period	49.54%	44.91%	+4.63%
Volatility (1Y) Calculated over the trailing 1-year period	79.90%	63.81%	+16.09%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	94.40%	60.36%	+34.04%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	94.40%	64.42%	+29.98%

Financials